Stereotactic and functional neurosurgery · 2025
Preoperative Treatment with Bisphosphonates Does Not Change the Thermal Response of Focused Ultrasound Thalamotomy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Henn Matthew C, Useinovic Nemanja, Cahill James, Shi Helen, Shafie Beck, Smith Haley, Joyce Molly, Valuev Tim, Lopez-Ramos Christian G, Raslan Ahmed M, Cleary Daniel R
Аннотация
INTRODUCTION: Skull density ratio (SDR) is an important criterion for predicting efficacy of high-intensity focused ultrasound (HIFU) thalamotomy for essential tremor and tremor-dependent Parkinson's disease. Bisphosphonates are known to increase bone density and are postulated to raise SDR and improve HIFU energy transmission efficiency. However, the impact of bisphosphonate pre-treatment on HIFU outcomes has not been investigated.
METHODS: A retrospective analysis was conducted on the sonication parameters of patients with SDR <0.45 who were pre-treated off-label with bisphosphonates prior to HIFU. For comparison, the sonication parameters were also collected for patients with SDR <0.45 not pre-treated with bisphosphonates, patients with mid-range SDR (0.45-0.49), and patients with high SDR (0.5-0.55). All patients underwent HIFU thalamotomy between March 2022 and December 2024.
RESULTS: The bisphosphonate pre-treatment group (28 patients) and the low-SDR untreated group (29 patients) both had mean SDRs of 0.41. Respectively, the bisphosphonate-treated and low-SDR untreated group had mean final sonication energy of 23 kJ versus 26 kJ, final sonication duration of 27.1 versus 28.6 s, mean maximum temperature of 52.8°C versus 53.2°C, and average of 5.6 versus 4.9 sonications per treatment (p > 0.05 for each comparison). No significant differences between the two low-SDR groups were found for the thermal efficiency of sonication. Compared to the bisphosphonate-treated low-SDR group, the mid- and high-SDR groups exhibited significantly decreased sonication energy (p < 0.0001), final sonication duration (p < 0.0001), and higher final sonication max temperature (p < 0.01). Across all patients, a negative correlation was observed between SDR and final sonication energy (p < 0.0001, r = -0.48) and a positive correlation was observed between SDR and last sonication temperature (p < 0.005, r = 0.27), although in the low-SDR cohort, a correlation was not observed. No clinically significant differences were found in demographics, self-reported tremor improvement, or incidence of side effects.
CONCLUSION: No significant differences were found in sonication response parameters between the bisphosphonate-treated and untreated low-SDR groups, whereas mid- and high-SDR groups had significantly reduced sonication energy and time to produce greater heat. These findings show that while bisphosphonates are an established way of raising bone density in osteoporosis, pre-treatment with bisphosphonates does not shift the sonication response from that of a low SDR to a mid-range SDR. Additionally, other factors besides just skull density likely determine the thermal response to sonication.
METHODS: A retrospective analysis was conducted on the sonication parameters of patients with SDR <0.45 who were pre-treated off-label with bisphosphonates prior to HIFU. For comparison, the sonication parameters were also collected for patients with SDR <0.45 not pre-treated with bisphosphonates, patients with mid-range SDR (0.45-0.49), and patients with high SDR (0.5-0.55). All patients underwent HIFU thalamotomy between March 2022 and December 2024.
RESULTS: The bisphosphonate pre-treatment group (28 patients) and the low-SDR untreated group (29 patients) both had mean SDRs of 0.41. Respectively, the bisphosphonate-treated and low-SDR untreated group had mean final sonication energy of 23 kJ versus 26 kJ, final sonication duration of 27.1 versus 28.6 s, mean maximum temperature of 52.8°C versus 53.2°C, and average of 5.6 versus 4.9 sonications per treatment (p > 0.05 for each comparison). No significant differences between the two low-SDR groups were found for the thermal efficiency of sonication. Compared to the bisphosphonate-treated low-SDR group, the mid- and high-SDR groups exhibited significantly decreased sonication energy (p < 0.0001), final sonication duration (p < 0.0001), and higher final sonication max temperature (p < 0.01). Across all patients, a negative correlation was observed between SDR and final sonication energy (p < 0.0001, r = -0.48) and a positive correlation was observed between SDR and last sonication temperature (p < 0.005, r = 0.27), although in the low-SDR cohort, a correlation was not observed. No clinically significant differences were found in demographics, self-reported tremor improvement, or incidence of side effects.
CONCLUSION: No significant differences were found in sonication response parameters between the bisphosphonate-treated and untreated low-SDR groups, whereas mid- and high-SDR groups had significantly reduced sonication energy and time to produce greater heat. These findings show that while bisphosphonates are an established way of raising bone density in osteoporosis, pre-treatment with bisphosphonates does not shift the sonication response from that of a low SDR to a mid-range SDR. Additionally, other factors besides just skull density likely determine the thermal response to sonication.